<p>Cosciens Biopharma Inc. (CSCIF) 发布了其第三季度财报。以下是 Cosciens Biopharma Inc. 向投资者展示的信息概述。</p>
<h3>认识您的 ETF AI 分析师</h3>
<ul>
<li>了解 TipRanks 的 <em>ETF</em> AI 分析师如何帮助您做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> AI 分析师</strong> 对您关注的 ETF 的见解。</li>
</ul>
<p>COSCIENS Biopharma Inc. 是一家专注于天然成分和制药解决方案的生命科学公司，已公布其 2025 年第三季度的财务业绩，强调了重要的战略举措。该公司专注于植物基活性成分和诊断产品的开发与商业化，最近已从纳斯达克退市，同时保持在多伦多证券交易所 (TSX) 的上市。</p>
<p>在 2025 年第三季度，COSCIENS 报告的合并净亏损为 180 万美元，相较于 2024 年同期的 580 万美元亏损有显著改善。这一净亏损的减少归因于公司的重组努力，使运营费用较去年减少了 59%。公司还报告总收入下降至 150 万美元，低于 2024 年第三季度的 190 万美元，主要是由于关键产品销售减少。</p>
<p>关键战略举措包括因电子商务渠道成功有限而暂停 Juvente Cosmeceuticals 产品线，并专注于将活性成分业务扩展到食品和饮料、皮肤病学和制药等新市场。此外，尽管在美国市场获得全面儿科批准面临挑战，COSCIENS 仍在探索其制药产品 Macrilen 的进一步开发机会。</p>
<p>展望未来，COSCIENS 旨在通过继续优化成本结构和探索新市场机会来提升运营效率和竞争力。该公司还寻求通过潜在的合作伙伴关系和许可机会扩大在美国市场的影响力，同时评估其专有 PGX 技术的商业化潜力。</p>

CSCIF

<p>Cosciens Biopharma Inc. (CSCIF) 发布了 2025 年第三季度财务报告，显示合并净亏损为 180 万美元，较 2024 年第三季度的 580 万美元有所改善。该公司已从纳斯达克退市，但仍在多伦多证券交易所上市。由于销售减少，总收入下降至 150 万美元，低于 190 万美元。战略举措包括暂停 Juvente Cosmeceuticals 产品线，并专注于将活性成分扩展到新市场。COSCIENS 旨在提高运营效率，并探索在美国市场的合作伙伴关系</p>

<p>Cosciens Biopharma Inc. ( (CSCIF) ) has released its Q3 earnings. Here is a breakdown of the information Cosciens Biopharma Inc. presented to its investors.</p>
<div class="lb-trans"><p>Cosciens Biopharma Inc. (CSCIF) 发布了其第三季度财报。以下是 Cosciens Biopharma Inc. 向投资者展示的信息概述。</p>
</div><h3>Meet Your ETF AI Analyst</h3>
<div class="lb-trans"><h3>认识您的 ETF AI 分析师</h3>
</div><ul>
<li>Discover how TipRanks' <em>ETF</em> AI Analyst can help you make smarter investment decisions</li>
<li>Explore ETFs TipRanks' users love and see what insights the <strong><em>ETF</em> AI Analyst</strong> reveals about the ones you follow.</li>
</ul>
<div class="lb-trans"><ul>
<li>了解 TipRanks 的 <em>ETF</em> AI 分析师如何帮助您做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> AI 分析师</strong> 对您关注的 ETF 的见解。</li>
</ul>
</div><p>COSCIENS Biopharma Inc., a life science company specializing in natural ingredients and pharmaceutical solutions, has reported its financial results for the third quarter of 2025, highlighting significant strategic initiatives. The company, which focuses on the development and commercialization of plant-based active ingredients and diagnostic products, has recently delisted from Nasdaq while maintaining its listing on the Toronto Stock Exchange (TSX).</p>
<div class="lb-trans"><p>COSCIENS Biopharma Inc. 是一家专注于天然成分和制药解决方案的生命科学公司，已公布其 2025 年第三季度的财务业绩，强调了重要的战略举措。该公司专注于植物基活性成分和诊断产品的开发与商业化，最近已从纳斯达克退市，同时保持在多伦多证券交易所 (TSX) 的上市。</p>
</div><p>In the third quarter of 2025, COSCIENS reported a consolidated net loss of $1.8 million, a notable improvement from the $5.8 million loss in the same period of 2024. This reduction in net loss is attributed to the company’s restructuring efforts, which have resulted in a 59% decrease in operating expenses compared to the previous year. The company also reported a decrease in total revenue to $1.5 million, down from $1.9 million in the third quarter of 2024, primarily due to reduced sales of key products.</p>
<div class="lb-trans"><p>在 2025 年第三季度，COSCIENS 报告的合并净亏损为 180 万美元，相较于 2024 年同期的 580 万美元亏损有显著改善。这一净亏损的减少归因于公司的重组努力，使运营费用较去年减少了 59%。公司还报告总收入下降至 150 万美元，低于 2024 年第三季度的 190 万美元，主要是由于关键产品销售减少。</p>
</div><p>Key strategic moves include the suspension of the Juvente Cosmeceuticals line due to limited success in e-commerce channels and a focus on expanding the active ingredients business into new markets such as food and beverage, dermatology, and pharmaceuticals. Additionally, COSCIENS is exploring further development opportunities for its pharmaceutical product Macrilen, despite challenges in achieving full pediatric approval in the U.S. market.</p>
<div class="lb-trans"><p>关键战略举措包括因电子商务渠道成功有限而暂停 Juvente Cosmeceuticals 产品线，并专注于将活性成分业务扩展到食品和饮料、皮肤病学和制药等新市场。此外，尽管在美国市场获得全面儿科批准面临挑战，COSCIENS 仍在探索其制药产品 Macrilen 的进一步开发机会。</p>
</div><p>Looking forward, COSCIENS aims to enhance its operational efficiency and competitiveness by continuing to streamline its cost structure and exploring new market opportunities. The company is also seeking to expand its presence in the U.S. market through potential partnerships and licensing opportunities, while evaluating the commercialization potential of its proprietary PGX technology.</p>
<div class="lb-trans"><p>展望未来，COSCIENS 旨在通过继续优化成本结构和探索新市场机会来提升运营效率和竞争力。该公司还寻求通过潜在的合作伙伴关系和许可机会扩大在美国市场的影响力，同时评估其专有 PGX 技术的商业化潜力。</p>
</div>

COSCIENS 生物制药公司发布 2025 年第三季度财务报告